-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $8

Benzinga·03/05/2025 10:41:23
Listen to the news
Canaccord Genuity analyst John Newman initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $8.